Summary: Joseph H. Griffith IV, chief financial officer at 908 Devices Inc., completed a sale of 23,175 common shares on February 2, 2026, for roughly $143,221. The transaction was executed at a weighted average price between $6.105 and $6.35, while the stock was trading near $6.44. The sale follows a large restricted stock unit settlement the prior day and comes as the company reports revenue growth for 2025 even as earnings per share remain in negative territory.
Griffith’s sale of 23,175 shares on February 2, 2026, generated approximately $143,221 in proceeds. The shares were sold at a weighted average price in the range of $6.105 to $6.35. At the time of the transaction, MASS was trading near $6.44, having appreciated 171.73% over the past year.
Separately, on February 1, 2026, Griffith received 70,035 shares of common stock when Restricted Stock Units settled. In addition to the RSU settlement, the CFO also acquired stock options and additional Restricted Stock Units as part of his compensation package. These movements in insider holdings occurred while the company’s market capitalization stood at $232 million.
On the company’s financials, preliminary unaudited figures for the full year 2025 indicate revenue of about $56 million, up roughly 17% from 2024. Preliminary fourth-quarter revenue is reported at approximately $17.2 million, a 20% increase compared with the same quarter a year earlier. Earlier results for Q3 2025 showed revenue of $14 million, beating a forecast of $13.52 million.
Despite the top-line improvements, earnings per share remain negative. The company reported an EPS loss of $0.41 for the referenced period, which missed a forecasted loss of $0.14. The combination of revenue growth and an EPS shortfall highlights a divergence between sales momentum and bottom-line profitability.
Balance sheet metrics noted alongside these developments show 908 Devices with more cash than debt and a current ratio of 3.49, signaling short-term liquidity. A Fair Value assessment included in recent analysis indicates the stock appears undervalued relative to that valuation benchmark. Additional premium research offerings are cited as providing further financial analysis and a set of preparatory insights ahead of the firm’s next earnings release scheduled for March 10, 2026.
Context for investors: The insider sale, the RSU settlement, and the company’s mixed financial signals are all relevant pieces for investors monitoring insider activity, revenue trends, liquidity metrics, and upcoming earnings. The market cap, preliminary revenue gains, and the liquidity ratio frame the company’s current financial posture, while the EPS miss underscores ongoing profitability challenges.